M1

The effect of new housing supply in structural models: a forecasting performance evaluation

Retrieved on: 
Sunday, February 4, 2024
BET, Section 2, Model, XT, CIT, LTV, Forecasting, Total, Bank, RT, Elasticity, GDP, Website, University of Chicago Press, Process control block, Fiscal, Reproduction, University, WTP, Johns Hopkins University Press, E32, Faculty, Writing, KMR, Monetary economics, Household, Root mean square, YT, GFC, Language, VAR, A6, Motivation, Growth, PLT, Hartman–Grobman theorem, Research, House, Observation, Friction, Section 4, Classification, Macroeconomic model, BAA, AP, Kálmán, Odyssean Wicca, Parameter, Blue chip, A5, HPT, Mark Gertler, Learning, Smets, Inflation, ECB, Q2, Trade, CE, Hit, SPF, Review of Economic Dynamics, ZBW, Kolasa, LTM, R21, Patient, Prior, Shock, Movement, ZT, Australasian, M1, Lens, Great, Nobuhiro, European Central Bank, Estimator, Policy, LTI, COVID-19, Attention, HP, Feedback, Goethe University Frankfurt, International Journal of Forecasting, Federal Reserve, Federal Reserve Bank, Behavior, Health, Blue Chip Economic Indicators, Inverse, Zero lower bound, The Blue, Journal of Applied Econometrics, Economic forecasting, Matrix, Economy, Federal, R31, LTP, Chinese Blackjack, WTI, CES, Sim, Bit, Section 5, Capital market, Quantitative Economics, Credit, Motion, Central bank, Journal of Political Economy, Political economy, Taylor & Francis, Journal of Monetary Economics, Act, Binning, CPT, DPT, Point, MCMC, RealTime, Literature, Metropolis–Hastings algorithm, ZLB, TFP, Research Papers in Economics, Del Negro, GBT, Communication, Kalman filter, Markov, Cycle, Business cycle, Eurozone, DFF, PDF, Filter, Medical classification, American Economic Journal, Demand shock, Comparison, Employment, KTEH, Cobb–Douglas production function, Nonprofit organization, Sampler, PTW, Par, Liquidity trap, Paper, Nominal interest rate, QT, Exercise, Monetary policy, RTD, Interest rate, A7, University of Cambridge, Control, Statistics, Posterior, Pressure, American Economic Review, E37, Financial intermediary, Social science, Basel II, Delphic, Depreciation, European Economic Review, HPD, Ai, Calendar, E17, Government, Journal of Econometrics, HTM, Freedom, LTE, Probability, Face, Calibration, Oxford University Press, New Keynesian economics, Sun, HH, Me, Uncertainty, FPI, Production, Dynamics, Handbook, Real estate

Key Points: 

    Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

    Retrieved on: 
    Saturday, January 27, 2024

    At 48 months, the estimated OS rate was 91.2% for patients who received KEYTRUDA compared to 86.0% for patients who received placebo.

    Key Points: 
    • At 48 months, the estimated OS rate was 91.2% for patients who received KEYTRUDA compared to 86.0% for patients who received placebo.
    • Treatment-related adverse events (TRAEs) occurred in 79.1% of patients (n=386) in the KEYTRUDA arm and 53.0% of patients (n=263) in the placebo arm.
    • Grade 3-4 TRAEs occurred in 18.6% of patients in the KEYTRUDA arm and 1.2% of patients in the placebo arm.
    • Treatment-related adverse events resulting in discontinuation of any treatment occurred in 18.2% of patients in the KEYTRUDA arm and 0.8% of patients in the placebo arm.

    BriefCam to Empower Businesses of all Sizes with New Innovative Analytics and Architecture Enhancements

    Retrieved on: 
    Tuesday, January 16, 2024

    One of the newest product offerings release with 2024 M1 is BriefCam Nexus which is designed for multi-site businesses.

    Key Points: 
    • One of the newest product offerings release with 2024 M1 is BriefCam Nexus which is designed for multi-site businesses.
    • With BriefCam Nexus, organizations can aggregate their single site video intelligence across multiple business locations into a single pane of glass.
    • “BriefCam Nexus transforms the way multi-site businesses develop strategies to positively impact several locations,” said Dana Keren, BriefCam Vice President of Product.
    • VIDEO SYNOPSIS® technology is a registered trademark of BriefCam, Ltd. For more information about BriefCam’s video content analytics solutions, visit www.BriefCam.com .

    CES 2024: 3i Presents Unprecedented and Fresh Solution for Odor Issues in Cat Litter Boxes with Auto-Pack Feature

    Retrieved on: 
    Wednesday, January 10, 2024

    So, we come to CES 2024 with our new product for pets," said Zexiao Wu, Vice President of 3i.

    Key Points: 
    • So, we come to CES 2024 with our new product for pets," said Zexiao Wu, Vice President of 3i.
    • "Most people in the 3i team have cats, and we can totally connect with some hassles of using a traditional cat litter box, such as odor, thin layers of litter leading to sticking, and more.
    • We are a team of creating products that address real-life issues, so here it is, the world's first intelligent odor-free cat litter box, the M1 series."
    • Certified by Frost & Sullivan, the 3i Intelligent Cat Litter Box is the world's first intelligent cat litter box with auto-pack and odor removal features in the global intelligent cat litter box market.

    RoboSense Announces New M Platform LiDAR Sensors at CES 2024

    Retrieved on: 
    Tuesday, January 9, 2024

    DETROIT, Jan. 9, 2024 /PRNewswire/ -- RoboSense, a leader in LiDAR and perception solutions, unveiled its latest M Platform line of sensors today at CES 2024. Following a successful IPO on the Hong Kong Stock Exchange, RoboSense continues to drive technological innovation by launching the M2, the ultimate mid-range LiDAR, and the M3, the M Platform's first long-range LiDAR. These products expand the company's robust portfolio of high-performance, cost-effective LiDAR sensors, advancing intelligent driving systems and autonomy in the automotive industry.

    Key Points: 
    • The cutting-edge M2 and M3 deliver increased range, resolution, and cost effectiveness to advance intelligent driving systems
      DETROIT, Jan. 9, 2024 /PRNewswire/ -- RoboSense , a leader in LiDAR and perception solutions, unveiled its latest M Platform line of sensors today at CES 2024.
    • Following a successful IPO on the Hong Kong Stock Exchange, RoboSense continues to drive technological innovation by launching the M2, the ultimate mid-range LiDAR, and the M3, the M Platform's first long-range LiDAR.
    • These products expand the company's robust portfolio of high-performance, cost-effective LiDAR sensors, advancing intelligent driving systems and autonomy in the automotive industry.
    • The commercialization of lidar has become a reality, and we believe our M2 and M3 products will allow us to accelerate the adoption of lidar for autonomous vehicles."

    Digital Check’s TellerScan, CheXpress Scanners Now Support macOS 14 “Sonoma”

    Retrieved on: 
    Thursday, January 4, 2024

    Northbrook, IL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Digital Check Corp., the world’s leading manufacturer of desktop check scanners, has added native support for Apple’s macOS 14 “Sonoma” to two of its most popular scanner models.

    Key Points: 
    • Northbrook, IL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Digital Check Corp., the world’s leading manufacturer of desktop check scanners, has added native support for Apple’s macOS 14 “Sonoma” to two of its most popular scanner models.
    • The TellerScan TS240 and CheXpress CX30 scanners, with a global install base of over 1 million devices, will now offer native support for macOS 14 when used with the latest version of the Digital Check API (DCC API).
    • This brings the company’s two highest-selling scanner models current with the most recent Mac operating system launched in September 2023.
    • Digital Check plans to include support for all new major releases of macOS in the future.

    EQS-News: M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result

    Retrieved on: 
    Saturday, December 30, 2023

    M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result

    Key Points: 
    • M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result
      The issuer is solely responsible for the content of this announcement.
    • M1 Kliniken AG publishes figures for the third quarter 2023:
      Group sales increase by over 10% to EUR 236.6 million in the first nine months of the 2023 financial year (previous year: EUR 214.2 million).
    • The operating result (Group EBIT) increases by over 98% to EUR 12.9 million (previous year: EUR 6.5 million).
    • EBIT rose by 98.2% to EUR 12.94 million (previous year: EUR 6.53 million), an increase of EUR 6.4 million.

    A New Milestone! WeRide Obtained the Singapore M1 and T1 Autonomous Vehicles Licenses

    Retrieved on: 
    Monday, December 11, 2023

    It is reported that the conditions for obtaining the M1 License in Singapore are extremely stringent.

    Key Points: 
    • It is reported that the conditions for obtaining the M1 License in Singapore are extremely stringent.
    • Vehicles must accurately and flawlessly complete the mentioned tasks within test facilities that highly replicate the urban road traffic scenarios in Singapore.
    • From the arrival of WeRide's Robobus at the Centre of Excellence for Testing and Research of Autonomous Vehicles in Singapore (CETRAN) on August 28th to the successful acquisition of both M1 and T1 licenses, WeRide accomplished this feat in just three months.
    • This achievement sets a record for the speed at which an autonomous driving company obtained licenses in Singapore.

    PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

    Retrieved on: 
    Friday, December 22, 2023

    The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.

    Key Points: 
    • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
    • ET
      PRINCETON, N.J. & BOSTON -- Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
    • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
    • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

    Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

    Retrieved on: 
    Friday, December 22, 2023

    Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.

    Key Points: 
    • Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
    • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
    • “There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space.
    • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.